Wade Huckabee Appointed Senior Vice President of BAT's Subsidiary

BAT by 2FIRSTS.ai

Jan.04.2024

Wade Huckabee Appointed Senior Vice President of BAT's Subsidiary

Wade Huckabee appointed as senior VP of Reynolds American Inc., subsidiary of British American Tobacco, overseeing strategy and transformation.

Wade Huckabee has been appointed as the Senior Vice President of Strategic and Transformation at RAI USA, a subsidiary of British American Tobacco (BAT), according to an official statement on the BAT website.

Hakobi's new position will take effect on January 1, 2024. He will be responsible for the strategic development and implementation in the United States, as well as serve the leadership team of Renault in America.

Hakabi joined Renault USA in April 2016 as the Vice President of Strategy and Planning. In this role, he was responsible for establishing more analytical capabilities and insights in the retail market. By December 2018, Hakabi was appointed as the Senior Vice President of Tobacco Business and later became the General Manager of Renault's Traditional Business Division in 2019.

In 2022, Hakabi was appointed as the Head of Global Revenue Growth, responsible for accelerating sales and category targets of the BAT Group in prioritized global markets. In 2023, he further took on the role of Head of Client and Business Group, responsible for the development of global trade marketing.

In his new role, Hakabi will lead and oversee Renault's strategies, including key elements related to business, organization, and regulatory policies.

Also Read:

[1] Texas Appellate Court: RJR Vapor Entitled to Over $16,000 Tax Refund

[2] Reynolds 337 Case: ITC may Initiate Investigation after November 13

#North America #United States #Traditional tobacco #Personnel appointment #British American Tobacco (BAT)

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.

Oct.20 by 2FIRSTS.ai

Philip Morris International and an Italian Design Brand Launch Limited-Edition IQOS Collaboration, Debuting in Japan Before Expanding to 13 Travel Retail Markets

Philip Morris International (PMI) has partnered with Italian design brand Seletti on a limited-edition IQOS collaboration, unveiled at Milan’s Pirelli HangarBicocca. The collection features two models, launching first in Japan before rolling out to 13 global travel retail markets. PMI says the partnership leverages design and cultural storytelling to advance its smoke-free transition.

Oct.28 by 2FIRSTS.ai

AG Miyares Argues Vape Ban Consistent with Federal Law, Seeks Dismissal

Virginia Attorney General Jason Miyares and Tax Commissioner James J. Alex have asked a federal court to dismiss a lawsuit challenging the state’s ban on flavored e-cigarettes. They argue plaintiffs lack standing because the products are already illegal under federal law. The state denies claims of federal preemption and asserts sovereign immunity, maintaining that its ban aligns with its authority to protect public health.

Nov.24 by 2FIRSTS.ai

Spain’s Competition Authority Questions Disposable Vape Ban

Spain’s National Commission on Markets and Competition (CNMC) has issued an opinion on the draft reform of the Tobacco Law proposed by the Ministry of Health, urging reconsideration of several measures. These include a proposed ban on disposable e-cigarettes and the full alignment of vaping products with traditional tobacco regulation.